Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has released topline data supporting the use of its anti-obesity drug Wegovy (semaglutide). The data originates from the SELECT cardiovascular outcomes trial, which enrolled an extensive cohort of 17,604 adults suffering from obesity and established cardiovascular disease (CVD), but without diabetes. This trial successfully achieved its primary endpoints, demonstrating that semaglutide 2.4mg resulted in a significant 20% reduction in major cardiovascular events (MACE) compared to placebo.
Plans for Label Indication Expansion
Armed with these significant findings, Novo Nordisk now intends to leverage the data to pursue label indication expansions for Wegovy in the US and the European Union later this year. This move could potentially broaden the drug’s application and accessibility for patients in need.
Upcoming Presentation of SELECT Trial Results
Detailed results from the SELECT trial are expected to be presented at a scientific conference later in 2023, offering the medical community a deeper insight into the drug’s cardiovascular benefits and its role in obesity treatment.-Fineline Info & Tech
